Rocket Pharmaceuticals to acquire Renovacor


The $53 million deal will create “strong synergies” by combining key assets, people, skills and intellectual property; while Rocket will receive Renovacor’s REN-001, an AAV-based gene therapy targeting BAG3-associated dilated cardiomyopathy (DCM), a severe form of heart failure (for which Rocket highlights Renovacor’s “convincing preclinical data”)

Headquartered in New Jersey, Rocket currently has four gene therapies in clinical trials. These include a phase 1 study for the rare genetic condition Danon disease; and it sees a “comparable, significant commercial opportunity” for BAG3-associated dilated cardiomyopathy.

“The acquisition of Renovacor is consistent with our strategy to expand our leadership position in AAV-based gene therapy for heart disease and gives us the perfect opportunity to continue our mission to transform the lives of heart failure patients through the power of gene therapy.”said Gaurav Shah, MD, CEO of Rocket.

Also Read :  The Future of Digital Health and Healthcare IT in a Post-Covid World

“Building on our success to date in Danon disease, I am particularly excited to expand our cardiology focus and capabilities and address a clear unmet medical need in BAG3-associated dilated cardiomyopathy. By combining Renovacor’s compelling preclinical work with our combined clinical, regulatory and CMC expertise, we believe we will be well-positioned to bring the highest impact and best chance of success gene therapy to these patients in the most productive and efficient way to deliver.

“Given the previously announced positive pediatric safety data from our Phase 1 RP-A501 Danon Disease program and the upcoming pediatric efficacy data and longer-term adult cohort data, we anticipate a presentation at the Heart Failure Society of America (HFSA) Scientific Meeting. At the end of this month, this strategic acquisition provides what we believe to be the broadest platform in this space to address these devastating rare heart diseases.

Also Read :  God of War Ragnarok Has a Side Quest That Is a Beautiful Tribute to a Developer Who Passed Away



Source link